Yes, Addyi (flibanserin) is a daily pill taken once nightly at bedtime.
Addyi must be taken as 100 mg once daily at bedtime—this is the FDA-approved dosing regimen for premenopausal women with hypoactive sexual desire disorder (HSDD). 1
Dosing Schedule
The medication is specifically dosed at bedtime (not during waking hours) because daytime administration significantly increases the risks of:
- Hypotension
- Syncope
- Accidental injury
- Central nervous system (CNS) depression 1
Patients must take this medication every night at bedtime for continuous treatment—it is not an "on-demand" medication taken before sexual activity. This distinguishes flibanserin from other sexual dysfunction treatments.
Key Clinical Considerations
Timeline for Effect
- Discontinue treatment after 8 weeks if no improvement is observed 1
- Clinical trials showed mean increases of approximately 1 additional satisfying sexual event every 2 months 2
- Improvements in sexual desire (measured by FSFI desire domain scores) and reductions in distress were statistically significant but modest 3, 4, 5, 6
Critical Safety Requirements
Alcohol interaction is the most important counseling point:
- Patients must wait at least 2 hours after consuming 1-2 standard alcoholic drinks before taking their bedtime dose
- If 3 or more drinks consumed that evening, skip the dose entirely
- Avoid alcohol until the following day after taking the bedtime dose 1
Activities requiring alertness:
- Avoid operating machinery or driving for at least 6 hours after each dose and until the patient knows how the medication affects them 1
- Common CNS effects include somnolence (8-12%), dizziness (10-11%), and fatigue (10%) 3, 4, 5
Contraindications (Absolute)
The medication is contraindicated in:
- Patients taking moderate or strong CYP3A4 inhibitors
- Patients with hepatic impairment of any degree 1
Drug Interactions to Monitor
- Oral contraceptives and weak CYP3A4 inhibitors increase flibanserin exposure and adverse event rates 1
- Strong CYP2C19 inhibitors increase exposure, raising hypotension/syncope risk 1
- Digoxin levels increase—monitor digoxin concentrations more frequently 1
- CYP3A4 inducers substantially reduce flibanserin concentrations; use not recommended 1
Evidence Quality Note
While flibanserin is FDA-approved and supported by multiple randomized controlled trials 3, 4, 5, 6, the clinical benefit is modest. The NCCN 2024 guidelines note it results in "approximately 1 additional satisfying sexual event every 2 months" 2. The ASCO 2018 guidelines specifically state "the risk/benefit ratio for this medication is uncertain" and note it has not been evaluated in women with cancer history or those on endocrine therapy 7.
The medication requires long-term daily commitment (potentially years in premenopausal women) with strict adherence to alcohol restrictions and bedtime dosing to minimize safety risks while achieving modest improvements in sexual desire and distress.